Other (Income)/Deductions - Net - Footnotes (Detail) - USD ($)		3 Months Ended			6 Months Ended
		Jul. 02, 2023		Jul. 03, 2022	Jul. 02, 2023		Jul. 03, 2022	May 31, 2023
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities	[1]	$ 121,000,000		$ (610,000,000)	$ (363,000,000)		$ (1,320,000,000)
Intangible asset impairment charge					248,000,000
Unsecured Debt [Member]
Loss Contingencies [Line Items]
Face amount of debt issued		31,000,000,000	[2],[3],[4]		31,000,000,000	[2],[3],[4]		$ 31,000,000,000
IPR&D [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[5]				94,000,000
Other Business Activities [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge	[5]				128,000,000
Operating Segments [Member] | IPR&D [Member] | Biopharma [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charge					120,000,000
BioNTech and Cerevel [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities				(432,000,000)			(776,000,000)
Cerevel [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities		202,000,000
BioNTech [Member]
Loss Contingencies [Line Items]
Unrealized gain (loss) on equity securities					(276,000,000)
Nimbus [Member]
Loss Contingencies [Line Items]
Dividend income					211,000,000
ViiV [Member]
Loss Contingencies [Line Items]
Dividend income		$ 91,000,000		$ 69,000,000	$ 183,000,000		$ 125,000,000

[1] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of July 2, 2023, there were cumulative impairments and downward adjustments of $170 million and upward adjustments of $200 million. Impairments, downward and upward adjustments were not significant in the second quarters and first six months of 2023 and 2022.

[2] The notes are fully and unconditionally guaranteed on a senior unsecured basis by Pfizer Inc. PIE was formed to finance a portion of the consideration for the proposed acquisition of Seagen and has no assets or operations and will have no assets or operations, other than as related to the issuance, administration and repayment of the notes and any other debt securities that it may issue in the future.

[3] The notes may be redeemed by us at any time, in whole, or in part, at a make-whole redemption price plus accrued and unpaid interest.

[4] The weighted average effective interest rate for the notes at issuance was 4.93%.

[5] Reflects intangible assets written down to fair value in 2023. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.